|Exhibit 99.1
|------------



|BRADLEY PHARMACEUTICALS FILES
LAWSUIT AGAINST DPT LAKEWOOD, INC.
|----------------------------------------------------------------



|Fairfield, NJ - February 25, 2003 - BRADLEY
PHARMACEUTICALS, INC. (NASDAQ: BPRX) today announced that it filed a patent
infringement, breach of confidentiality agreement and misappropriation of trade secrets
action against DPT Lakewood, Inc., a wholly owned subsidiary of DPT Laboratories Ltd.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|In its complaint filed today in the United
States District Court for the  District of New Jersey, Bradley alleges that DPT breached
a confidentiality  agreement with Bradley and misappropriated Bradleys trade secrets
relating to  Carmol(R) 40 Cream, Bradleys 40% urea cream. In the complaint, Bradley
further  alleges that DPT is infringing Bradleys composition patent for dermatological
products comprised of 40% urea. During 1999, Bradley had provided, in accordance  with a
confidentiality agreement entered into for the possible manufacture of  Bradleys
Carmol(R) 40 Cream, substantial trade secret information to a company  since acquired by
DPT, including processing methods and formulations essential  to the manufacture of
Carmol(R) 40 Cream.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|DPT currently manufactures a 40% urea cream for
Dermik Laboratories and Aventis  Pharmaceuticals. Bradley recently filed a patent
infringement lawsuit against  Dermik and Aventis alleging that the marketing and sale by
Dermik and Aventis of  their 40% urea cream infringes three of Bradleys patents, a
composition patent  for dermatological products comprised of 40% urea and two methodology
patents  for the therapeutic use of urea-based products.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|In addition to a judicial determination that DPT
infringed Bradleys proprietary  patent, Bradley is seeking triple monetary damages for
willful infringement,  disgorgement of all profits resulting from the infringement of
Bradleys patent,  punitive and other appropriate damages for DPTs misappropriation of
Bradleys  trade secrets and preliminary and permanent injunctions enjoining DPT from
manufacturing any urea or other product that infringes on Bradleys patents.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Bradley Pharmaceuticals President and CEO,
Daniel Glassman, stated, Bradley  remains committed to vigorously protecting the
integrity, validity and  enforceability of the Companys intellectual property and
proprietary patents to  the fullest extent permitted by law. In addition, Bradley will
commit the full  extent of its marketing and sales resources, including its greatly
expanded  sales force, to reinforce and strengthen its relations with the dermatology and
podiatry communities.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Except for historical and factual information,
this press release contains  forward-looking statements within the meaning of
the Private Securities  Litigation Reform Act of 1995. These forward-looking statements
include  statements that address activities, events or developments that Bradley expects,
believes or anticipates will or may occur in the future, such as earnings  estimates and
predictions of future financial performance. All forward-looking  statements are based on
assumptions made by Bradley based on its experience and  perception of historical trends,
current conditions, expected future  developments and other factors it believes are
appropriate under the  circumstances. These statements are subject to numerous risks and
uncertainties,  many of which are beyond Bradleys control, including Bradleys ability
to  maintain Carmol(R) sales and the outcome of related pending litigation,  effectively
purchase or integrate new products into its portfolio or effectively  react to other
risks described from time to time in Bradleys SEC filings.  Further, Bradley cannot
predict the impact on its business of any
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | 
| |  | 



---





|future  approvals of generic versions of its
products or of other competing products. No  forward-looking statement can be guaranteed,
and actual results may differ  materially from those projected. Bradley undertakes no
obligation to publicly  update any forward-looking statement, whether as a result of new
information,  future events or otherwise.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Bradley Pharmaceuticals, Inc., is a specialty
pharmaceutical company marketing  prescription niche therapies to highly targeted
physician audiences in the  United States and in 34 international markets. Dermatology
brands are delivered  by the Doak Dermatologics subsidiary and the Kenwood Therapeutics
division  provides gastroenterology, nutritional and respiratory therapies. Following the
strategy Acquire, Enhance, Grow, the company has achieved success by acquiring  and
managing the life cycle of brands that fill unmet needs.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | 
| |  | 



---